降压药早上吃还是晚上吃？真的有讲究！
Ranking
No observed public metrics; popularity remains neutral/archived.
Merged summary
TL;DR - A WeChat clinical-education piece from 医学界 that walks through the evidence on morning vs. bedtime antihypertensive dosing, framed as a demo of "DrSeek," an evidence-retrieval AI assistant inside the 医学界医生站 app. It matters as an example of RAG-style clinical decision support being productized for Chinese physicians at the point of care.
- The AI tool is positioned for evidence triage: each clinical claim in the article is presented as a "click to experience" DrSeek query output, i.e. literature synthesis on demand rather than physician recall.
- Cited evidence includes a 2025 JAMA RCT (n=3,357, ~5-year follow-up) showing no significant difference in death or major cardiovascular events between bedtime and morning dosing, but higher long-term adherence in the morning group (88% vs. 70%).
- For non-dipper hypertension, cited systematic-review data show bedtime dosing lowers nocturnal systolic BP by 8.62 mmHg; evening telmisartan restored normal dipping in 73% of non-dippers, and evening lacidipine in 47.1% vs. 18.8% for morning dosing.
- Stated decision logic: individualize by ambulatory-BP-confirmed rhythm type and drug class, with caution in patients >65 with nocturnal hypotension risk, sleep apnea, or orthostatic hypotension. The article carries an explicit disclaimer that content accuracy is not guaranteed — a notable caveat for AI-assisted clinical content.
Sources (1)
降压药早上吃还是晚上吃？真的有讲究！
TL;DR - A WeChat clinical-education piece from 医学界 that walks through the evidence on morning vs. bedtime antihypertensive dosing, framed as a demo of "DrSeek," an evidence-retrieval AI assistant inside the 医学界医生站 app. It matters as an example of RAG-style clinical decision support being productized for Chinese physicians at the point of care.
- The AI tool is positioned for evidence triage: each clinical claim in the article is presented as a "click to experience" DrSeek query output, i.e. literature synthesis on demand rather than physician recall.
- Cited evidence includes a 2025 JAMA RCT (n=3,357, ~5-year follow-up) showing no significant difference in death or major cardiovascular events between bedtime and morning dosing, but higher long-term adherence in the morning group (88% vs. 70%).
- For non-dipper hypertension, cited systematic-review data show bedtime dosing lowers nocturnal systolic BP by 8.62 mmHg; evening telmisartan restored normal dipping in 73% of non-dippers, and evening lacidipine in 47.1% vs. 18.8% for morning dosing.
- Stated decision logic: individualize by ambulatory-BP-confirmed rhythm type and drug class, with caution in patients >65 with nocturnal hypotension risk, sleep apnea, or orthostatic hypotension. The article carries an explicit disclaimer that content accuracy is not guaranteed — a notable caveat for AI-assisted clinical content.